RecruitingPhase 4

Staphylococcus Aureus Network Adaptive Platform Trial

United States, Australia8,000 participantsStarted 2022-02-16

Plain-language summary

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Staphylococcus aureus complex grown from ≥1 blood culture
✓. Admitted to a participating hospital at the time of eligibility assessment (OR if patient has died, they were admitted to this site anytime from the time of blood culture collection until the time of eligibility assessment)

Exclusion criteria

✕. Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture (Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative)
✕. Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician.
✕. Known previous participation in the randomised SNAP platform
✕. Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment
✕. Treating team deems enrolment in the study is not in the best interest of the patient
✕. Treating team believes that death is imminent and inevitable
✕. Patient is for end-of-life care and antibiotic treatment is considered not appropriate
✕. Patient \<18 years of age and paediatric recruitment not approved at recruiting site

What they're measuring

All-cause mortality at 90 days after platform entry

Timeframe: From randomisation (day 1) until day 90

Trial details

NCT IDNCT05137119

SponsorUniversity of Melbourne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-01

Contact for this trial

Lauren Barina

+61 (03) 8344 1623 lauren.barina@unimelb.edu.au

View on ClinicalTrials.gov More Staphylococcus Aureus Bacteremia trials